Switch theme
Sign up to access all valuation multiples
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
2014
6K+
LTM Revenue $5.8B
LTM EBITDA $806M
$5.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chemours has a last 12-month revenue (LTM) of $5.8B and a last 12-month EBITDA of $806M.
In the most recent fiscal year, Chemours achieved revenue of $5.8B and an EBITDA of $692M.
Chemours expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chemours valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.8B | XXX | $5.8B | XXX | XXX | XXX |
| Gross Profit | $1.3B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Margin | 21% | XXX | 20% | XXX | XXX | XXX |
| EBITDA | $806M | XXX | $692M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $477M | XXX | $443M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $203M | XXX | $86.0M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Chemours's stock price is $13.
Chemours has current market cap of $1.9B, and EV of $5.8B.
See Chemours trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.8B | $1.9B | XXX | XXX | XXX | XXX | $1.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Chemours has market cap of $1.9B and EV of $5.8B.
Chemours's trades at 1.0x EV/Revenue multiple, and 8.4x EV/EBITDA.
Equity research analysts estimate Chemours's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chemours has a P/E ratio of 9.3x.
See valuation multiples for Chemours and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $5.8B | XXX | $5.8B | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | 7.2x | XXX | 8.4x | XXX | XXX | XXX |
| EV/EBIT | 12.2x | XXX | 13.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 9.3x | XXX | 21.8x | XXX | XXX | XXX |
| EV/FCF | -15.7x | XXX | -5.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChemours's last 12 month revenue growth is 3%
Chemours's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.1M for the same period.
Chemours's rule of 40 is 6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chemours's rule of X is 22% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Chemours and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 104% | XXX | XXX | XXX |
| Rule of 40 | 6% | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chemours acquired XXX companies to date.
Last acquisition by Chemours was XXXXXXXX, XXXXX XXXXX XXXXXX . Chemours acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Chemours founded? | Chemours was founded in 2014. |
| Where is Chemours headquartered? | Chemours is headquartered in United States of America. |
| How many employees does Chemours have? | As of today, Chemours has 6K+ employees. |
| Who is the CEO of Chemours? | Chemours's CEO is Ms. Denise M. Dignam. |
| Is Chemours publicy listed? | Yes, Chemours is a public company listed on NYS. |
| What is the stock symbol of Chemours? | Chemours trades under CC ticker. |
| When did Chemours go public? | Chemours went public in 2015. |
| Who are competitors of Chemours? | Similar companies to Chemours include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of Chemours? | Chemours's current market cap is $1.9B |
| What is the current revenue of Chemours? | Chemours's last 12 months revenue is $5.8B. |
| What is the current revenue growth of Chemours? | Chemours revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Chemours? | Current revenue multiple of Chemours is 1.0x. |
| Is Chemours profitable? | Yes, Chemours is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Chemours? | Chemours's last 12 months EBITDA is $806M. |
| What is Chemours's EBITDA margin? | Chemours's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Chemours? | Current EBITDA multiple of Chemours is 7.2x. |
| What is the current FCF of Chemours? | Chemours's last 12 months FCF is -$368M. |
| What is Chemours's FCF margin? | Chemours's last 12 months FCF margin is -6%. |
| What is the current EV/FCF multiple of Chemours? | Current FCF multiple of Chemours is -15.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
